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Background-—Little is known about the association of atrial ﬁbrillation symptom burden with quality of life and outcomes.
Methods and Results-—In the Prevention of Thromboembolic Events–European Registry in Atrial Fibrillation (n=6196 patients with
atrial ﬁbrillation; meanSD age, 71.810.4 years; 39.7% women), we assessed European Heart Rhythm Association score
symptoms and calculated correlations with the standardized health status questionnaire (EQ-5D-5L). Patients were followed up for
atrial ﬁbrillation therapies and outcomes (stroke/transient ischemic attack/arterial thromboembolism, coronary events, heart
failure, and major bleeding) over 1 year. Most individuals (92%) experienced symptoms. Correlations with health status and quality
of life were modest. In multivariable-adjusted regression models, the dichotomized European Heart Rhythm Association score
(intermediate/frequent versus never/occasional symptoms) was associated with cardioversions (odds ratio [OR], 1.21; 95%
conﬁdence interval [CI], 1.01–1.45) and catheter ablation (OR, 1.97; 95% CI, 1.44–2.69), and inversely related with heart rate
control (OR, 0.80; 95% CI, 0.70–0.92) and heart failure incidence (OR, 1.65; 95% CI, 1.16–2.34). Anxiety was inversely related with
stroke/transient ischemic attack/arterial thromboembolism (OR, 0.55; 95% CI, 0.32–0.93), whereas chest pain related positively
with coronary events (OR, 2.45; 95% CI, 1.42–4.22). Fatigue (OR, 1.84; 95% CI, 1.30–2.60), dyspnea (OR, 2.33; 95% CI, 1.63–3.33),
and anxiety (OR, 1.72; 95% CI, 1.16–2.55) were associated with heart failure incidence. Palpitations were positively associated with
cardioversion (OR, 1.32; 95% CI, 1.08–1.61) and ablation therapy (OR, 2.02; 95% CI, 1.48–2.76).
Conclusions-—A higher symptom burden, in particular palpitations, predicted interventions to restore sinus rhythm. The score itself
had limited predictive value, but its individual components were related to different and speciﬁc clinical events, and may thus be
helpful to target patient management. ( J Am Heart Assoc. 2018;7:e007559. DOI: 10.1161/JAHA.117.007559.)
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A trial ﬁbrillation (AF) is a frequent cardiovascular diseasewith a high symptom burden compromising daily life.1 The European Heart Rhythm Association (EHRA) score hasbeen suggested to assess symptom quality and the impairment
in everyday activities caused by arrhythmia-related symptoms.
The score evaluates 6 symptom dimensions (palpitations,
fatigue, dizziness, dyspnea, chest pain, and anxiety) in 4
severities, ranging from none to symptom frequency that leads
to a discontinuation of daily activities. Such a score was
encouraged as a simple, but relatively speciﬁc, quantiﬁcation of
AF-related symptoms that permits the assessment of func-
tional impairment attributable to AF.2,3 It may serve as a
measure of quality of life (QoL) and of the limitations in
everyday activities. It was validated as a useful semiquantita-
tive classiﬁcation of health status and as an indicator of health
utility in a monocentric study in a specialized clinic.4 To date,
the EHRA score has not been related to AF-related interven-
tions and meaningful outcomes in large cohorts. In asymp-
tomatic patients with AF, mortality during 1 year appeared to
be higher compared with individuals with symptomatic AF.5 In
AF outpatients, EHRA score category ≥2 was related to more
frequent hospitalizations and possibly higher bleeding risk.6
Whether AF-related symptom burden, reﬂected by the EHRA
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score, is associated with cardiovascular disease outcomes in
AF remains largely unknown. In this context, the Prevention of
Thromboembolic Events–European Registry in Atrial Fibrilla-
tion7 provided the opportunity to prospectively examine the
score and its different dimensions in a contemporary European
cohort. We focused on temporal stability of symptoms:
symptoms as potential triggers for therapeutic interventions
during 1-year follow-up. Furthermore, we examined the
predictive ability of the score for common adverse events,
such as thromboembolism, heart failure, coronary events, and
major bleeding, in patients with AF after 1 year.
Methods
We cannot make the individual data available without
restrictions attributable to limitations of consent. We will
look into possibilities to make access to the original data
available on request. Data sets analyzed during this study may
be made available on request from Daiichi Sankyo Europe.
Ethics Approval and Consent to Participate
Responsible local Ethics Committees, as required by national
regulations in Austria, Germany, Switzerland, Italy, Spain, and
the United Kingdom, approved the study before the start of
enrollment. In France, no speciﬁc approval was needed
because of the noninterventional nature of the study.
Study Sample
Over 1 year (2012–2013), 7243 patients aged ≥18 years with
AF were recruited from 7 European countries (France,
Germany, Austria, Switzerland, Italy, Spain, and the United
Kingdom)7 into the Prevention of Thromboembolic Events–
European Registry in Atrial Fibrillation and followed up for
12 months, with the last follow-up in January 2014. Patients
were enrolled in 461 centers, mostly cardiology practices and
hospitals. Follow-up information was collected by physician-
administered questionnaire and supplemented from medical
records. Because of incomplete longitudinal information, 831
individuals were excluded.
Clinical Variables
Clinical Characteristics
AF was based on a physician’s diagnosis and was documented
by an ECG or a cardiac device (pacemaker/deﬁbrillator). The
enrolling physician provided information on anthropometric
data, disease history, current clinical presentation, medica-
tions, and cardiovascular interventions. The EHRA score was
assessed for palpitations, fatigue, dizziness, dyspnea, chest
pain, and anxiety.3 Symptom frequency was classiﬁed as
never, occasional (less than once per month), intermediate
(once per month to almost daily), and frequent (at least daily).
The maximum category of any of the 6 individual symptoms
resulted in the EHRA score. If information on any of the EHRA
symptom dimensions was missing at baseline, patients were
excluded, leaving 6196 individuals for the analysis.
We further assessed QoL by validated questionnaires on
preference-based measures of health. The EQ-5D-5L provides
preference-based health-related utility to assess cost-
effectiveness.8 The Perception of Anti-Coagulant Treatment
Questionnaire (PACT-Q) was speciﬁcally designed to quan-
tify expectations and treatment satisfaction with oral
anticoagulation.9 Sample items of both questionnaires are
provided in Tables S1 and S2.
Interventions and outcomes
We collected information on pharmacological or electrical
cardioversion attempts during follow-up, as well as catheter-
basedablation therapy.Asoutcomes,weassessed thepresence
of sinus rhythm on the follow-up ECG and adequate heart rate
control. The latter was deﬁned as a heart rate between 60 and
100 beats per minute during the clinic visit. Disease outcomes
were ischemic stroke/transient ischemic attack/arterial embo-
lism, coronary events (acute coronary syndrome/coronary
revascularization), heart failure, and major bleeding. Heart
failure was deﬁned as a physician-diagnosed condition or
reduced left ventricular ejection fraction. Major bleeding com-
prised cerebrovascular bleeding and major gastrointestinal or
other bleeding events usually requiring blood transfusion.
Statistical Analyses
From 7243 patients, 831 (11.5%) did not have a follow-up
visit. Therefore, the data analysis was performed with
Clinical Perspective
What Is New?
• Most patients with atrial ﬁbrillation are symptomatic (>90%),
and the symptom burden slightly decreases during 1 year of
follow-up.
• The European Heart Rhythm Association symptoms score
and its components are moderately related to quality of life,
health care use, and cardiovascular outcomes.
• Palpitations are predictive of interventions (cardioversion
and ablation therapy) to restore sinus rhythm.
What Are the Clinical Implications?
• Compared with other European Heart Rhythm Association
symptoms, palpitations appear to be strong triggers of
interventions to restore and maintain sinus rhythm.
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complete EHRA score information at baseline and follow-up in
6196 patients. At baseline, 2.98% of the patients had missing
values. To determine the assumption of missing completely at
random, we compared the baseline characteristics of the
individuals used for the analyses and the patients excluded
from the analyses. We did not observe signiﬁcant differences
in the distribution of baseline variables (Table S3).
Variables are presented as meanSD for continuous
variables and number (percentage) for discrete variables. In
a multivariable stepwise selection model, we calculated b
estimates and F values in relation to the EHRA score.
To understand correlations with other metrics of QoL,
Spearman rank correlation coefﬁcients for the EHRA score
and its components with EQ-5D-5L and PACT-Q items were
calculated.
We examined symptom stability over 1 year comparing the
proportion of individuals in each EHRA symptom category at
baseline and follow-up by the McNemar test. We tested for
interactions by cardioversion or ablation therapy during
follow-up.
We performed multiple logistic regression models for the
EHRA score as a categorical variable and for each symptom
dimension separately using ANCOVA across categories in
relation to interventions and adverse cardiovascular events.
Because of small numbers in the EHRA score categories 1 and
4, we also dichotomized the EHRA score into class 3/4 versus
1/2. Odds ratios (ORs) for the different EHRA classes
compared with EHRA score 1 are provided in the Supple-
mental Material. We chose outcomes on the basis of end
points suggested in the literature.1 Interventions included
cardioversions (pharmacological and electrical cardioversion)
and catheter-based ablation (pulmonary vein isolation). Major
dichotomous adverse cardiovascular outcomes were ischemic
stroke/transient ischemic attack/arterial thromboembolic
events, coronary events (acute coronary syndrome, including
myocardial infarction and unstable angina pectoris, and
coronary revascularization), heart failure, and major bleeding.
We adjusted for age, sex, and country. In a second model, we
additionally adjusted for body mass index, systolic blood
pressure/hypertension, diabetes mellitus, current smoking,
heart failure, and myocardial infarction. The model examining
incident heart failure excluded individuals with heart failure at
baseline (N=1723) and patients with missing information
about heart failure at baseline (N=165). We chose predictors
and potential confounding variables because they have been
related to symptoms, disease severity, and outcomes (Data
S1).
For adjusted analyses, we used multivariable logistic
regression model ﬁtted via the SAS procedure logistic. We
calculated P values derived by bootstrapping for the clinical
variables to assess the predictive accuracy (Table S4). We
also analyzed the area under the curves from resubstitution
and from 10-fold cross validation for the following: (1) the
whole model and the EHRA components and (2) the partial
model and the EHRA components provided in Tables S5 and
S6.
For all the analyses, we used SAS software, version 9.4
(SAS Institute, Cary, NC). A 2-tailed threshold of 0.05 was
chosen to indicate statistical signiﬁcance. Our analyses are
exploratory in nature.
Results
Baseline Characteristics
Baseline characteristics of the sample are provided in Table 1.
The mean age was 72 years, and 40% were women. Patients
showed a substantial cardiovascular risk factor burden and a
Table 1. Baseline Characteristics of the Study Sample
Characteristics Value (N=6196)
Age, y 71.810.4
Female sex, N (%) 2460 (39.7)
Body mass index, kg/m2 27.95.0
Systolic blood pressure, mm Hg 131.516.5
Hypertension, N (%) 4514 (73.3)
Ever smoking, N (%) 2331 (39.7)
Alcohol abuse, N (%) 157 (2.6)
Diabetes mellitus, N (%) 1368 (22.3)
Dyslipidemia, N (%) 2697 (44.5)
History of myocardial infarction, N (%) 663 (10.7)
Heart failure, N (%) 1723 (28.6)
History of ischemic stroke/TIA/other
ischemic-thromboembolic event, N (%)
924 (15.1)
EHRA score ≥2, N (%) 5695 (91.9)
History of cardioversion and/or ablation, N (%) 2147 (34.7)
Interventions during 1 y, N (%)
Cardioversion 701 (11.3)
Catheter-based ablation 226 (3.4)
Outcomes over 1 y, N (%)
Stroke/TIA/arterial thromboembolic events 136 (2.2)
Coronary events 140 (2.3)
Heart failure 155 (2.5)
Major bleeding 168 (2.7)
Sinus rhythm 2022 (32.6)
Adequate heart rate 2734 (44.1)
Data are presented as meanSD for continuous variables and number (percentage) for
discrete variables. In some patients, different variables were missing, as seen from the
numbers. EHRA indicates European Heart Rhythm Association; TIA, transient ischemic
attack.
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high prevalence of cardiovascular disease, with 10% previ-
ous myocardial infarction, 30% prevalent heart failure, and
15% previous stroke/transient ischemic attack/other
ischemic-thromboembolic events. Most patients were symp-
tomatic; 92% indicated an EHRA score ≥2. The characteristics
of individuals excluded because of missing EHRA score
information are shown in Table S7.
Strongest clinical correlates of the EHRA score selected
from clinical variables in the baseline table were heart failure
and female sex. Furthermore, ever smoking, a history of
cardioversion and/or ablation, body mass index, and, with
smaller estimates, diabetes mellitus and a history of myocar-
dial infarction were selected (Table 2). Ten-fold cross-valida-
tion P values showed comparable results (Table S4).
Correlations With Other Metrics of QoL
Although correlations between EHRA score and its compo-
nents with EQ-5D-5L achieved statistical signiﬁcance for most
bivariate correlations, the strength was moderate (Table 3).
The highest Spearman correlation coefﬁcient was observed
between EHRA score and the ability to perform usual activities
(rs=0.308, P<0.0001). The maximum correlation for compo-
nents of the EHRA score was seen for dyspnea and usual
activities (rs=0.339, P<0.0001).
Spearman correlation coefﬁcients of the EHRA score and
PACT-Q items are shown in Table S8. Despite statistical
signiﬁcance, the correlations were weak.
Symptom Development Over Time
In the Figure, we show the proportion of EHRA symptom
severity for the 6 dimensions on enrollment and after 1 year.
Fatigue was most frequently reported. Only 26.4% of patients
at baseline and 32.1% at follow-up never had symptoms of
fatigue. The least frequent symptom of the 6 symptoms of the
EHRA score was chest pain, which was never experienced by
70.5% of patients at baseline and 77.6% of patients at follow-
up. Most individuals (92%) experienced at least 1 symptom.
Over 1 year, symptom severity appeared to improve for all
EHRA dimensions (P<0.001). The largest reduction in symp-
tom frequency was observed for palpitations. The highest
symptom stability (ie, patients staying in the same category at
baseline and follow-up) was seen for chest pain (72.8%),
dizziness (61.5%), and anxiety (57.7%). These last 3 symptom
dimensions did not show signiﬁcant interactions with car-
dioversion or ablation therapy. The EHRA score, palpitations,
fatigue, and dyspnea showed statistically signiﬁcant interac-
tions by cardioversion and ablation therapy, with a larger
improvement when these interventions were performed
successfully, even after adjustment for antiarrhythmic drug
use. Results for the unadjusted model are provided in
Table S9.
EHRA Score Symptoms and Interventions
In Table 4, we provide risk factor–adjusted logistic regression
analyses for EHRA score and EHRA symptom dimensions
separately in relation to interventions to restore sinus rhythm
for EHRA score class 3/4 (intermediate/frequent) versus 1/2
(never/occasional).
EHRA score as a categorical variable was statistically
signiﬁcantly associated with cardioversion therapy (OR, 1.22;
95% conﬁdence interval [CI], 1.01–1.45; P=0.0398) and
catheter-based ablation procedures (OR, 1.97; 95% CI,
1.44–2.69; P<0.0001); and it was inversely associated with
adequate heart rate control (OR, 0.80; 95% CI, 0.70–0.92;
P=0.0015) at follow-up. In 10-fold cross validation, the
statistical signiﬁcance of these interventions remained similar
(Table S5). Of the symptoms investigated, a high symptom
burden of palpitations was predictive of cardioversion therapy,
ablation, and the presence of sinus rhythm at follow-up, and it
was inversely correlated with adequate heart rate control.
Statistical signiﬁcance was more frequently achieved when
assessed across all categories. Results for the unadjusted
model are provided in Table S10.
Table 2. Multivariable Stepwise Selection Model for Clinical Correlates of EHRA Score at Baseline
Variables Partial R2 Model R2 b Value F Value P Value
Female sex 0.0230 0.0590 0.3610.025 139.47 <0.0001
Ever smoking 0.0104 0.0694 0.1900.026 62.68 <0.0001
History of cardioversion and/or ablation 0.0043 0.0737 0.1240.024 26.21 <0.0001
Body mass index, kg/m² 0.0031 0.0769 0.0110.002 18.87 <0.0001
Diabetes mellitus 0.0008 0.0776 0.0650.029 4.73 0.030
History of myocardial infarction 0.0008 0.0785 0.0860.038 5.03 0.025
Heart failure 0.0360 0.0360 0.3870.026 208.49 <0.0001
All variables from Table 1 were permitted to enter the analysis. Partial R2 is provided for the variation in EHRA score explained by the clinical variable. b, the regression coefﬁcient, shows
estimated change in EHRA score for 1-unit increment in body mass index or the condition present for categorical variables. EHRA indicates European Heart Rhythm Association.
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Clinical Outcomes
The EHRA score was associated with heart failure incidence
during 1 year (OR, 1.65; 95% CI, 1.16–2.34; P=0.0053)
(Table 5). Anxiety was inversely related with stroke (OR, 0.55;
95% CI, 0.32–0.93; P=0.0245). Chest pain was associated
with coronary events (OR, 2.45; 95% CI, 1.42–4.22; P=0.001).
Fatigue (OR, 1.84; 95% CI, 1.30–2.60; P=0.0006), dyspnea
(OR, 2.33; 95% CI, 1.63–3.33; P<0.0001), and anxiety (OR,
1.72; 95% CI, 1.16–2.55; P=0.0069) were associated with the
incidence of heart failure. None of the EHRA score symptoms
were predictive of major bleeding events. P values derived
from 10-fold cross validation are provided in Table S6. Results
for the unadjusted model are provided in Table S10. Tables
S11 through S15 provide the multivariable adjusted results
for EHRA score categories separately, with EHRA class 1 as
the reference. Unadjusted models are presented in Tables
S14 through S16.
Discussion
Main Findings
In a contemporary cohort of patients with AF, the EHRA score
and its different symptom dimensions were moderately
correlated with commonly used measures of QoL in AF. The
score was predictive of interventions to restore sinus rhythm.
Among symptoms, only palpitations were consistently related
to interventions and rhythm at 1 year. Although the score
itself was not strongly related to outcomes, different symptom
dimensions were speciﬁcally predictive of cardiovascular
outcomes (ie, anxiety for stroke; chest pain for coronary
events; and fatigue, dyspnea, and anxiety for incident heart
failure).
Symptom burden and QoL
The EHRA score has been recommended to speciﬁcally
quantify AF-related symptom burden.3 It has been validated
with a moderate correlation with the Atrial Fibrillation Effect
on Quality-of-Life questionnaire.4,6 Prior studies reported a
strong negative correlation between the EHRA class and QoL
assessed by components of the EQ-5D. We can demonstrate
a weak correlation of EHRA score or its different symptom
dimensions with EQ-5D-5L. Generic QoL measures mirror
general functioning and well-being. They may be confounded
by general characteristics of patients with AF, such as age,
and lack potentially treatable dimensions that are speciﬁc to
AF.10 No relevant association was shown for PACT-Q. This
ﬁnding is plausible, because the PACT-Q was developed to
assess expectations and treatment satisfaction with
Table 3. Spearman Correlation Coefﬁcients for the EHRA Score and Its Components With EQ-5D-5L
EHRA Score Anxiety Chest Pain Palpitations Dyspnea Fatigue Dizziness
Mobility (5 levels)
0.26876 0.14588 0.16897 0.26876 0.30645 0.28930 0.20188
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Self-care (5 levels)
0.19867 0.16513 0.17959 0.11487 0.23563 0.18963 0.19849
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Usual activities (5 levels)
0.30837 0.18304 0.21227 0.13342 0.33949 0.31344 0.24013
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Pain/discomfort (5 levels)
0.23616 0.18290 0.21180 0.10504 0.26378 0.25211 0.24013
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Anxiety/depression (5 levels)
0.27861 0.47612 0.17020 0.10504 0.20609 0.22386 0.18526
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Visual analogue scale (your health today) (numerical)
0.28372 0.21182 0.21887 0.13869 0.30841 0.31414 0.22712
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Spearman’s rs is provided in the top row, and the corresponding P value is in the bottom row. EHRA indicates European Heart Rhythm Association.
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AF-related anticoagulation,9 but not necessarily effects of AF
on health-related well-being.
Symptoms in relation to interventions
In the European AF guidelines, the EHRA score is recom-
mended to tailor treatment for symptoms.11 In our cohort, the
EHRA score was a strong predictor of cardioversion and
catheter-based ablation procedures during a 1-year follow-up.
A higher symptom burden has clearly been associated with
ablation therapy.4 The score is most widely used by electro-
physiologists who are crucial in the decision process to
initiate therapies to restore sinus rhythm.
Among the different symptom dimensions of the EHRA
score, palpitations were signiﬁcantly predictive of interven-
tions to restore sinus rhythm. In addition, they were
correlated with the presence of sinus rhythm and, inversely,
with heart rate control, at follow-up. Palpitations are a
common symptom and fairly speciﬁc in the setting of AF. If a
regular rhythm can be achieved, symptoms resolve, which
may explain the predictive ability for rhythm control
treatment.4 Palpitations thus appear to be a trigger to search
for ways to restore and maintain sinus rhythm. In patients
with perceived irregular heartbeat, sinus rhythm was more
frequently reached rather than heart rate control. The latter
was inversely associated with palpitations. The largest
reduction in symptom burden over 1 year also was demon-
strated for palpitations. Thus, palpitations appear to receive
high attention and are targeted as a marker of successful
treatment. On the other hand, it needs to be considered that
palpitations may be subject to least recall bias and may
therefore show stronger associations than other EHRA score
components. Other symptom dimensions were not consis-
tently related to interventions and rhythm. Fatigue and
dyspnea signiﬁcantly improved after successful cardioversion
and ablation therapies and could be considered as triggers for
interventions to improve AF symptom burden.
In our study, the overall symptom burden was high, which
may be explained by the speciﬁc assessment of all EHRA
symptom dimensions required by the protocol. There was a
trend towards a lower symptom burden after 1 year, which
may indicate the success of regular follow-up by a cardiologist
for the reduction of symptoms, which is a major goal of AF
treatment. In particular, we observed signiﬁcant interactions
for cardioversion and ablation therapy that were related to a
reduced symptom burden. It is well known that AF-related
therapy helps to improve symptom burden.12–14 In a prior
observational study, QoL in patients with newly diagnosed AF
reached normal values under pharmacologic therapy and
cardioversion.15 In this context, our data also show that EHRA
score symptoms are sensitive to changes related to AF
management over 1 year, an important quality of symptom
measurement scales.
Symptom burden and outcomes
In our sample, the overall symptom burden measured by the
EHRA score showed an association with the incidence of
Figure. Distribution of European Heart Rhythm Association score categories across the 6 symptom dimensions at baseline and after 1 year.
Percentages are provided for each category.
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heart failure, but not with other cardiovascular outcomes. Our
ﬁndings are in line with evidence from the literature.
Symptomatic patients (EHRA score ≥2) did not show an
increased risk of stroke, myocardial infarction, or mortality in
the Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation.6 Asymptomatic individuals in the AFFIRM (Atrial
Fibrillation Follow-Up Investigation of Rhythm Management)
trial had a comparable prognosis after accounting for clinical
confounders,16 and asymptomatic subclinical AF carries a
signiﬁcant risk of thromboembolic events.17 In other studies,
hospitalizations have been reported to be more frequent in
patients with symptoms, and they may have driven
Table 4. Multivariable-Adjusted Logistic Regression Analyses for EHRA Score and EHRA Symptom Dimensions Separately in
Relation to Interventions to Restore Sinus Rhythm at 1 Year
Variable
Odds Ratio
for EHRA 3/4 Versus 1/2 95% Conﬁdence Interval P Value
P Value
(Adjusted Logistic Regression
Across All 4 Categories)
Cardioversion, N=701 (11.3%)
Palpitations 1.32 1.08 to 1.61 0.0073 <0.0001
Fatigue 1.16 0.97 to 1.39 0.11 0.18
Dizziness 1.27 0.98 to 1.64 0.07 0.32
Dyspnea 1.05 0.86 to 1.27 0.65 0.79
Chest pain 1.37 0.97 to 1.93 0.08 0.20
Anxiety 0.79 0.63 to 0.99 0.042 0.08
EHRA score 1.21 1.01 to 1.45 0.040 0.07
Catheter-based ablation, N=226 (3.4%)
Palpitations 2.02 1.48 to 2.76 <0.0001 <0.0001
Fatigue 1.67 1.23 to 2.26 0.0009 0.0017
Dizziness 1.11 0.70 to 1.75 0.65 0.90
Dyspnea 1.19 0.84 to 1.68 0.26 0.008
Chest pain 1.41 0.79 to 2.52 0.24 0.25
Anxiety 1.26 0.88 to 1.80 0.21 0.20
EHRA score 1.97 1.44 to 2.69 <0.0001 <0.0001
Sinus rhythm at 1 y, N=2022 (32.6%)
Palpitations 1.51 1.30 to 1.76 <0.0001 <0.0001
Fatigue 0.98 0.86 to 1.12 0.76 0.93
Dizziness 0.90 0.74 to 1.10 0.31 0.75
Dyspnea 0.86 0.74 to 0.99 0.033 0.003
Chest pain 1.44 1.90 to 1.10 0.0085 0.012
Anxiety 1.04 0.89 to 1.22 0.60 0.007
EHRA score 1.06 0.93 to 1.20 0.40 0.048
Adequate heart rate control, N=2734 (44.1%)
Palpitations 0.81 0.68 to 0.95 0.012 0.031
Fatigue 0.86 0.74 to 0.99 0.036 0.03
Dizziness 1.004 0.82 to 1.23 0.97 0.23
Dyspnea 0.88 0.76 to 1.02 0.10 0.16
Chest pain 0.84 0.62 to 1.14 0.27 0.51
Anxiety 0.91 0.76 to 1.07 0.25 0.51
EHRA score 0.80 0.70 to 0.92 0.0015 0.005
Odds ratios are provided for EHRA score category 3/4 vs 1/2. P values across all 4 categories are from logistic regression analyses, as implemented in SAS proc logistic. All models are
adjusted for age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, heart failure, and history of myocardial infarction. EHRA indicates
European Heart Rhythm Association.
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associations with combined cardiovascular outcomes.6,18,19
Symptoms per se, combined in the EHRA score, do not appear
to be strongly predictive of adverse events. Therefore, in line
with our data, overall symptom severity does not carry a high
prognostic utility.
In contrast, speciﬁc symptoms of the EHRA score, which
overlap with other cardiovascular disease entities, appear to be
more relevant for prognosis. Chest pain was a comparatively
uncommon symptom in the Prevention of Thromboembolic
Events–European Registry in Atrial Fibrillation, but it was
Table 5. Multivariable-Adjusted Logistic Regression Analyses for EHRA Score and EHRA Symptom Dimensions Separately in
Relation to Cardiovascular Outcomes at 1 Year
Variable
Odds Ratio
for EHRA 3/4 Versus 1/2 95% Conﬁdence Interval P Value
P Value
(Adjusted Logistic Regression
Across All 4 Categories)
Stroke/TIA/arterial thromboembolic events, N=136 (2.2%)
Palpitations 0.92 0.58 to 1.46 0.72 0.29
Fatigue 1.04 0.72 to 1.51 0.82 0.92
Dizziness 1.32 0.82 to 2.13 0.26 0.002
Dyspnea 1.04 0.71 to 1.53 0.84 0.59
Chest pain 1.69 0.92 to 3.10 0.09 0.002
Anxiety 0.55 0.32 to 0.93 0.025 0.08
EHRA score 1.02 0.70 to 1.49 0.92 0.05
Coronary events, N=140 (2.3%)
Palpitations 0.98 0.60 to 1.60 0.95 0.21
Fatigue 1.09 0.75 to 1.58 0.64 0.73
Dizziness 1.16 0.70 to 1.91 0.57 0.72
Dyspnea 1.32 0.90 to 1.93 0.16 0.02
Chest pain 2.45 1.42 to 4.22 0.001 <0.0001
Anxiety 1.41 0.91 to 2.18 0.13 0.33
EHRA score 1.45 0.99 to 2.13 0.06 0.12
Heart failure, N=155 (2.5%)
Palpitations 1.14 0.74 to 1.76 0.56 0.42
Fatigue 1.84 1.30 to 2.60 0.0006 0.0006
Dizziness 1.50 0.93 to 2.41 0.10 0.19
Dyspnea 2.33 1.63 to 3.33 <0.0001 <0.0001
Chest pain 1.25 0.57 to 2.75 0.58 0.42
Anxiety 1.72 1.16 to 2.55 0.0069 0.03
EHRA score 1.65 1.16 to 2.34 0.0053 0.005
Major bleeding, N=168 (2.7%)
Palpitations 0.88 0.55 to 1.41 0.59 0.78
Fatigue 1.27 0.90 to 1.79 0.17 0.28
Dizziness 1.08 0.67 to 1.74 0.74 0.90
Dyspnea 0.92 0.64 to 1.34 0.67 0.61
Chest pain 0.91 0.42 to 1.98 0.81 0.74
Anxiety 1.21 0.80 to 1.83 0.36 0.46
EHRA score 1.09 0.77 to 1.54 0.64 0.60
Odds ratios are provided for EHRA score category 3/4 vs 1/2 in a multivariable-adjusted model. P values across all 4 categories are from logistic regression analyses, as implemented in
SAS proc logistic. Covariates are age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, heart failure, and history of myocardial infarction.
Coronary events comprised acute coronary syndrome and coronary revascularization. The model for incident heart failure does not include adjustment for heart failure. EHRA indicates
European Heart Rhythm Association; TIA, transient ischemic attack.
DOI: 10.1161/JAHA.117.007559 Journal of the American Heart Association 8
Symptoms and Outcomes in Atrial Fibrillation Schnabel et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 8, 2019
strongly related to coronary events. The inverse association of
anxiety with stroke is likely a spurious ﬁnding because of the
comparatively small number of strokes. Prior cohort studies
demonstrated an increased stroke risk in individuals with
anxiety.20 In patients with AF, anxiety may be related to better
compliance and medication adherence, however we could
not demonstrate clear evidence to prove these assumption in
our data. Fatigue and dyspnea, classic symptoms of heart failure,
were associated with incident disease. Thus, speciﬁc symptoms
needtobetaken intoaccount seriously inclinical practiceandmay
require targeted workup to possibly avoid disease complications.
Limitations
Inherent to registry data from different centers, bias
attributable to enrollment decisions, quality of data collection,
and follow-up may have been introduced, despite training of
the participating cardiologists and central data management.
In addition, the EHRA score calculation in practice often is
more subjective, and it shows less measurement accuracy
because we used the maximum severity achieved for any of
the symptom dimensions, which resulted in a relatively high
symptom burden and may slightly impair the comparability
with common practice. Compared with a recent study,21 the
proportion of interventions (cardioversions or catheter-based
ablation therapies) was small, which may indicate a slightly
older and sicker patient sample with more permanent AF and
may reduce the generalizability to younger patients.
On the other hand, our large data set provides valuable
insights into current symptom-related health care patterns,
treatment decisions, and outcomes.
In conclusion, our prospective data in a contemporary cohort
with AF show that the EHRA symptom score and its components
aremoderately related to QoL and health utility of cardioversion
and ablation therapy, and they predict a higher proportion of
sinus rhythm after 1 year. Although the EHRA score is not
strongly related to outcomes, its speciﬁc components should
be considered to assess patients’ prognosis. Thus, the EHRA
score or slight modiﬁcations of it appear to be useful for clinical
workup, which needs to be proved in future trials.
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Supplementary Methods Literature evidence for the selection of predictor variables and 
potential confounders 
Variables Reference 
Age 1-4
Gender  1-4
Body mass index 5-7
Systolic blood pressure 5,6
Hypertension 1,4
Smoking 8,9
Alcohol intake 9-11
Diabetes mellitus 1,4
Dyslipidaemia 8,9
History of myocardial infarction 3,5
Heart failure 1,12
History of ischemic stroke/TIA 1,4,13
History of cardioversion and/or ablation 1
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3 
Supplementary Table 1. Selected items from the EQ-5D-5L Questionnaire 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities  
I have slight problems doing my usual activities  
I have moderate problems doing my usual activities  
I have severe problems doing my usual activities  
I am unable to do my usual activities   
We would like to know how good or bad your health is TODAY.  
This scale is numbered from 0 to 100. 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
• Mark an X on the scale to indicate how your health is TODAY.
• Now, please write the number you marked on the scale in the box below.
YOUR HEALTH TODAY = 
EQ-5D™ is a trade mark of the EuroQol Group. 
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Supplementary Table 2. Selected items from the Perception of Anticoagulant Treatment 
Questionnaire (PACT-Q)14 
B1 - How difficult is it to take your anticoagulant treatment (e.g., pills or injections, number of pills or 
injections, frequency of intake ...)? 
1 2 3 4 5 
Not at all A little Moderately Very Extremely 
C1 - Because of potential side effects (e.g., minor bruises, bleeding…), do you limit your usual 
activities (i.e., work, leisure, social, or physical activities…)? 
1 2 3 4 5 
Not at all A little Moderately A lot Completely 
D1 - How reassured do you feel by your anticoagulant treatment? 
1 2 3 4 5 
Not at all A little Somewhat Very Completely 
D3 - How did your experience with side effects such as minor bruises or bleeding (e.g., while 
shaving, cooking, after small cuts…) compare to what you expected? 
1 2 3 4 5 
It is much worse 
than what I 
expected 
It is worse than 
what I expected 
It is exactly what 
I expected 
It is better than 
what I expected 
It is much better 
than what I 
expected 
D7 - Overall, how satisfied are you with your anticoagulant treatment? 
1 2 3 4 5 
Extremely 
dissatisfied 
Dissatisfied Neither satisfied 
nor dissatisfied 
Satisfied Extremely 
satisfied 
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Supplementary Table 3 Baseline characteristics of the patients entering the analyses 
compared to patients excluded from the analyses due to missing follow-up information or 
missing EHRA data at baseline 
Variables 
Study sample   
N= 6196 
Excluded due to 
missing  
N=1047* 
P Value 
Age, years (SD) 71.8±10.4 70.7±12.1 0.13 
Female gender, N (%) 2460 (39.7) 426 (41.4) 0.32 
Body mass index, kg/m² (SD) 27.9±5.0 28.0±5.0 0.68 
Systolic blood pressure, mm Hg (SD) 131.5±16.5 132.1±17.6 0.11 
Hypertension, N (%) 4514 (73.3) 727 (71.2) 0.16 
Ever smoking, N (%) 2331 (39.7) 382 (39.2) 0.61 
Alcohol abuse, N (%) 157 (2.6) 25 (2.6) 0.99 
Diabetes mellitus, N (%) 1368 (22.3) 249 (24.4) 0.14 
Dyslipidaemia, N (%) 2697 (44.5) 436 (43.6) 0.61 
History of myocardial infarction, N (%) 663 (10.7) 110 (10.7) 0.97 
Heart failure, N (%) 1723 (28.6) 263 (26.4) 0.17 
History of ischemic stroke/TIA/other 
ischemic-thromboembolic event, N (%) 
924 (15.1) 149 (14.9) 0.91 
EHRA score ≥2, N (%) 5695 (91.9) 889 (92.9) 0.30 
History of cardioversion and/or ablation, 
N (%) 
2147 (34.7) 381 (37.6) 0.07 
Data are presented as mean and standard deviation for continuous and percentages for 
discrete variables.  
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Supplementary Table 4 Multivariable stepwise selection model for variables correlates of EHRA score 
at baseline 
Variables Partial 
R² 
Model R² β F Value P Value P Value* 
Female gender 0.0230 0.0590 0.361±0.025 139.47 <0.0001 <0.0001 
Ever smoking 0.0104 0.0694 0.190±0.026 62.68 <0.0001 <0.0001 
History of cardioversion 
and/or ablation 0.0043 0.0737 0.124±0.024 26.21 <0.0001 0.001 
Body mass index, kg/m² 0.0031 0.0769 0.011±0.002 18.87 <0.0001 0.005 
Diabetes mellitus 0.0008 0.0776 -0.065±0.029 4.73 0.03 0.06 
History of myocardial 
infarction 0.0008 0.0785 0.086±0.038 5.03 0.03 0.04 
Heart failure 0.0360 0.0360 0.387±0.026 208.49 <0.0001 <0.0001 
All variables from Table 1 were permitted to enter the analysis. Partial R² is provided for the variation in 
EHRA score explained by the clinical variable. β, the regression coefficient, shows estimated change in 
EHRA score for one unit increment in body mass index or the condition present for categorical variables. 
*P Value derived by bootstrapping. At 91% of stepwise selection models from 1000 runs of bootstrapping
a subset of presented variables was selected.
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 Supplementary Table 5 Multivariable-adjusted logistic regression analyses for EHRA score and EHRA symptom dimensions separately in relation 
to interventions to restore sinus rhythm at one year 
Variable Odds 
ratio 
EHRA 3/4 
versus 
1/2 
95%  
Confidence interval 
P Value P Value 
adjusted 
logistic 
regression. 
across all 4 
categories 
AUC –  
resubstitution 
AUC – 10-fold 
cross validation 
P- Value
10-fold
cross
validation 
Cardioversio, N=701 (11.3%) 
Palpitations 1.32 1.08 1.61 0.007 <0.0001 0.682/0.548 0.621/0.539 0.009 
Fatigue 1.16 0.97 1.39 0.11 0.18 0.678/0.520 0.601/0.513 0.19 
Dizziness 1.27 0.98 1.64 0.07 0.32 0.678/0.508 0.560/0.506 0.39 
Dyspnea 1.05 0.86 1.27 0.65 0.79 0.676/0.507 0.592/0.506 0.76 
Chest pain 1.37 0.97 1.93 0.08 0.20 0.679/0.510 0.604/0.509 0.23 
Anxiety 0.79 0.63 0.99 0.04 0.08 0.677/0.507 0.603/0.506 0.35 
EHRA score 1.21 1.01 1.45 0.040 0.07 0.679/0.534 0.616/0.533 0.04 
Catheter-based ablation, N=226 (3.4%) 
Palpitations 2.02 1.48 2.76 <0.0001 <0.0001 0.808/0.599 0.715/0.574 <0.0001 
Fatigue 1.67 1.23 2.26 0.0009 0.002 0.800/0.545 0.691/0.535 0.007 
Dizziness 1.11 0.70 1.75 0.65 0.90 0.796/0.504 0.688/0.503 0.91 
Dyspnea 1.19 0.84 1.68 0.26 0.008 0.796/0.511 0.690/0.509 0.27 
Chest pain 1.41 0.79 2.52 0.24 0.25 0.797/0.510 0.689/0.507 0.34 
Anxiety 1.26 0.88 1.80 0.21 0.20 0.797/0.521 0.692/0.518 0.23 
EHRA score 1.97 1.44 2.69 <0.0001 <0.0001 0.804/0.568 0.708/0.550 0.0003 
Sinus rhythm at one year, N=2022 (32.6%) 
Palpitations 1.51 1.30 1.76 <0.0001 <0.0001 0.706/0.551 0.651/0.550 0.0004 
Fatigue 0.98 0.86 1.12 0.76 0.93 0.702/0.520 0.640/0.514 0.83 
Dizziness 0.90 0.74 1.10 0.31 0.75 0.702/0.514 0.638/0.510 0.84 
Dyspnea 0.86 0.74 0.99 0.033 0.003 0.703/0.538 0.644/0.530 0.04 
Chest pain 1.44 1.90 1.10 0.009 0.01 0.703/0.505 0.641/0.504 0.54 
Anxiety 1.04 0.89 1.22 0.60 0.007 0.702/0.512 0.641/0.510 0.61 
EHRA score 1.06 0.93 1.20 0.40 0.048 0.702/0.501 0.628/0.501 0.97 
Adequate heart rate control, N=2734 (44.1%) 
Palpitations 0.81 0.68 0.95 0.012 0.03 0.565/0.516 0.550/0.515 0.05 
Fatigue 0.86 0.74 0.99 0.04 0.03 0.560/0.511 0.544/0.510 0.18 
Dizziness 1.00 0.82 1.23 0.97 0.23 0.558/0.501 0.537/0.501 0.99 
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Variable Odds 
ratio 
EHRA 3/4 
versus 
1/2 
95%  
Confidence interval 
P Value P Value 
adjusted 
logistic 
regression. 
across all 4 
categories 
AUC –  
resubstitution 
AUC – 10-fold 
cross validation 
P- Value
10-fold
cross
validation 
Dyspnea 0.88 0.76 1.02 0.10 0.16 0.559/0.508 0.541/0.506 0.44 
Chest pain 0.84 0.62 1.14 0.27 0.51 0.559/0.505 0.540/0.504 0.61 
Anxiety 0.91 0.76 1.07 0.25 0.51 0.560/0.502 0.538/0.502 0.82 
EHRA score 0.80 0.70 0.92 0.001 0.005 0.565/0.521 0.551/0.519 0.04 
Odds ratios are provided for EHRA score category 3/4 versus 1/2. P-values across all 4 categories are from logistic regression analyses as implemented 
in SAS proc logistic. All models are adjusted for age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, 
heart failure, history of myocardial infarction. AUCs (area under the curve) are for the whole model/ partial EHRA component. 
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Supplementary Table 6 Multivariable-adjusted logistic regression- and area under the curve analysis for EHRA score and EHRA symptom dimensions 
separately in relation to cardiovascular outcomes at one year 
Variable Odds 
ratio 
EHRA 3/4 
versus 
1/2 
95%  
Confidence interval 
P Value P Value 
adjusted 
logistic 
regression 
across all 4 
categories 
AUC –  
resubstitution 
AUC – 10-fold 
cross validation 
P-value
10-fold
cross
validation 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 (2.2%) 
Palpitations 0.92 0.58 1.46 0.72 0.29 0.707/0.502 0.641/0.502 0.86 
Fatigue 1.04 0.72 1.51 0.82 0.92 0.706/0.535 0.639/0.517 0.88 
Dizziness 1.32 0.82 2.13 0.26 0.002 0.706/0.526 0.642/0.521 0.36 
Dyspnea 1.04 0.71 1.53 0.84 0.59 0.706/0.547 0.643/0.527 0.55 
Chest pain 1.69 0.92 3.10 0.09 0.002 0.704/0.526 0.645/0.522 0.14 
Anxiety 0.55 0.32 0.93 0.03 0.08 0.711/0.521 0.653/0.520 0.06 
EHRA score 1.02 0.70 1.49 0.92 0.05 0.706/0.540 0.646/0.519 0.88 
Coronary events,  
N=140 (2.3%) 
Palpitations 0.98 0.60 1.60 0.95 0.21 0.725/0.515 0.645/0.512 0.97 
Fatigue 1.09 0.75 1.58 0.64 0.73 0.724/0.533 0.649/0.520 0.65 
Dizziness 1.16 0.70 1.91 0.57 0.72 0.725/0.512 0.647/0.510 0.59 
Dyspnea 1.32 0.90 1.93 0.16 0.024 0.726/0.559 0.654/0.532 0.18 
Chest pain 2.45 1.42 4.22 0.001 <0.0001 0.734/0.546 0.657/0.543 0.02 
Anxiety 1.41 0.91 2.18 0.13 0.33 0.727/0.513 0.652/0.511 0.40 
EHRA score 1.45 0.99 2.13 0.06 0.12 0.727/0.560 0.654/0.542 0.07 
Heart failure,  
N=155 (2.5%) 
Palpitations 1.14 0.74 1.76 0.56 0.42 0.639/0.508 0.568/0.506 0.71 
Fatigue 1.84 1.30 2.60 0.0006 0.0006 0.656/0.576 0.609/0.557 0.005 
Dizziness 1.50 0.93 2.41 0.10 0.19 0.644/0.523 0.588/0.518 0.21 
Dyspnea 2.33 1.63 3.33 <0.0001 <0.0001 0.669/0.598 0.615/0.580 <0.0001 
Chest pain 1.25 0.57 2.75 0.58 0.42 0.637/0.502 0.570/0.502 0.94 
Anxiety 1.72 1.16 2.55 0.007 0.032 0.648/0.545 0.590/0.543 0.04 
EHRA score 1.65 1.16 2.34 0.005 0.005 0.653/0.567 0.592/0.555 0.02 
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Variable Odds 
ratio 
EHRA 3/4 
versus 
1/2 
95%  
Confidence interval 
P Value P Value 
adjusted 
logistic 
regression 
across all 4 
categories 
AUC –  
resubstitution 
AUC – 10-fold 
cross validation 
P-value
10-fold
cross
validation 
Major bleeding, 
N=168 (2.7%) 
Palpitations 0.88 0.55 1.41 0.59 0.78 0.651/0.516 0.581/0.513 0.67 
Fatigue 1.27 0.90 1.79 0.17 0.28 0.656/0.541 0.592/0.531 0.20 
Dizziness 1.08 0.67 1.74 0.74 0.90 0.650/0.509 0.582/0.507 0.78 
Dyspnea 0.92 0.64 1.34 0.67 0.61 0.651/0.520 0.583/0.512 0.73 
Chest pain 0.91 0.42 1.98 0.81 0.74 0.651/0.501 0.578/0.500 0.98 
Anxiety 1.21 0.80 1.83 0.36 0.46 0.651/0.517 0.584/0.516 0.40 
EHRA score 1.09 0.77 1.54 0.64 0.60 0.652/0.529 0.583/0.514 0.69 
Odds ratios are provided for EHRA score category 3/4 versus 1/2. P-values across all 4 categories are from logistic regression analyses and additionally 
from 10-fold cross validation implemented in SAS proc logistic. All models are adjusted for age, sex, country, body mass index, systolic blood pressure, 
hypertension, diabetes mellitus, smoking, heart failure, history of myocardial infarction. AUCs (area under the curve) are for the whole model/ partial EHRA 
component and measured for resubstitution and 10-fold cross validation. Dow
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Supplementary Table 7. Baseline characteristics of individuals excluded due to missing 
information on any EHRA score 
Variables N=216 
Age, years (SD) 70.4±11.4 
Female gender, N (%) 39.8% (86) 
Body mass index, kg/m² (SD) 28.8±5.7 
Systolic blood pressure, mm Hg (SD) 129±21 
Hypertension, N (%) 66.7% (144) 
Ever smoking, N (%) 45.5% (75) 
Alcohol abuse, N (%) 3.4% (6) 
Diabetes mellitus, N (%) 25.0% (54) 
Dyslipidaemia, N (%) 41.7% (83) 
History of myocardial infarction, N (%) 12.5% (27) 
Heart failure, N (%) 41.5% (80) 
History of ischemic stroke/TIA/other 
ischemic-thromboembolic event, N (%) 18.5% (37) 
Data are presented as mean and standard deviation for continuous variables and number 
and percentages. Other variables were also partly incomplete in these patients as seen 
from the numbers. 
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Supplementary Table 8. Spearman correlation coefficients for the EHRA score and its 
components with PACT- Q items 
EHRA Score Anxiety Chest pain Palpitations Dyspnoea Fatigue Dizziness 
[B1] How difficult is it to take your anticoagulant treatment (e.g., pills or injections, 
number of pills or injections, frequency of intake ...)? 
0.10546 
<0.0001 
0.16633 
<0.0001 
0.10594 
<0.0001 
0.17954 
<0.0001 
0.10539 
<0.0001 
0.09543 
<0.0001 
0.09072 
<0.0001 
[B2] How bothered are you by taking your anticoagulant treatment? 
0.12898 
<0.0001 
0.19448 
<0.0001 
0.12898 
<0.0001 
0.20222 
<0.0001 
0.10518 
<0.0001 
0.11116 
<0.0001 
0.07323 
<0.0001 
[B3] Some anticoagulant treatments may need dose adjustments; how difficult is this for 
you? 
0.12773 
<0.0001 
0.19594 
<0.0001 
0.12075 
<0.0001 
0.19115 
<0.0001 
0.10951 
<0.0001 
0.12683 
<0.0001 
0.09478 
<0.0001 
[B4] Certain medications cannot be taken at all while you are on anticoagulant 
treatments; how difficult is this for you? 
0.12383 
<0.0001 
0.20048 
<0.0001 
0.10256 
<0.0001 
0.20647 
<0.0001 
0.11369 
<0.0001 
0.12825 
<0.0001 
0.09460 
<0.0001 
[B5] It is recommended that certain foods be avoided while taking an anticoagulant 
treatment; how difficult is this for you? 
0.07683 
<0.0001 
0.18530 
<0.0001 
0.11705 
<0.0001 
0.18827 
<0.0001 
0.07738 
<0.0001 
0.10838 
<0.0001 
0.09460 
<0.0001 
[B6] How difficult is it for you to take your anticoagulant treatment when you are away 
from home? 
0.10162 
<0.0001 
0.16068 
<0.0001 
0.12057 
<0.0001 
0.10201 
<0.0001 
0.09191 
<0.0001 
0.10385 
<0.0001 
0.06483 
<0.0001 
[B7] How difficult is it for you to plan your time around your anticoagulant treatment 
(e.g., appointments with nurses, doctors or labs...)? 
0.14566 
<0.0001 
0.17336 
<0.0001 
0.14388 
<0.0001 
0.21822 
<0.0001 
0.12125 
<0.0001 
0.13797 
<0.0001 
0.06483 
<0.0001 
D
ow
nloaded from
 http://ahajournals.org by on November 8, 2019
13 
Supplementary Table 8. Spearman correlation coefficients for the EHRA score and its 
components with PACT- Q items (continued) 
EHRA Score Anxiety Chest pain Palpitations Dyspnoea Fatigue Dizziness 
 
 [B8] How bothered are you by the medical follow-up required with your anticoagulant 
treatment? 
0.08453 
<0.0001 
0.18823 
<0.0001 
0.11752 
<0.0001 
0.20081 
<0.0001 
0.05842 
<0.0001 
0.09220 
<0.0001 
0.08461 
<0.0001 
[B9] How difficult is it for you to take your anticoagulant  treatment as directed on a  
regular basis? 
0.12537 
<0.0001 
0.16171 
<0.0001 
0.11651 
<0.0001 
0.21103 
<0.0001 
0.09063 
<0.0001 
0.10710 
<0.0001 
0.08525 
<0.0001 
[B10] Do you feel more dependent on others (e.g., partner, family, nurse) because of 
your anticoagulant treatment? 
0.17240 
<0.0001 
0.18311 
<0.0001 
0.12693 
<0.0001 
0.16914 
<0.0001 
0.17195 
<0.0001 
0.16955 
<0.0001 
0.08525 
<0.0001 
[B11] How worried are you about having to interrupt or stop your anticoagulant 
treatment? 
0.13061 
<0.0001 
0.20338 
<0.0001 
0.12549 
<0.0001 
0.15611 
<0.0001 
0.17195 
<0.0001 
0.11834 
<0.0001 
0.08525 
<0.0001 
[C1] Because of potential side effects (e.g., minor bruises, bleeding...), do you limit your 
usual activities (i.e., work, leisure, social, or physical activities...)? 
0.15334 
<0.0001 
0.18924 
<0.0001 
0.14262 
<0.0001 
0.18691 
<0.0001 
0.15104 
<0.0001 
0.15889 
<0.0001 
0.14754 
<0.0001 
[D1] How reassured do you feel by your anticoagulant treatment? 
-0.07108
<0.0001
-0.10681
<0.0001
-0.10686
<0.0001
-0.10521
<0.0001
-0.7081
<0.0001
-0.08733
<0.0001
-0.07081
<0.0001
[D2] Do you feel that your anticoagulant treatment has decreased your symptoms (e.g., 
leg pain or swelling, palpitations, shortness of breath, or chest pain...)? 
-0.05842
<0.0001
-0.06600
<0.0001
0.00986 
0.5077 
-0.05842
<0.0001
-0.02086
<0.0001
-0.06279
<0.0001
0.04011 
<0.0001 
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Spearman’s rs is provided in the upper, the corresponding P-value in the lower row. 
Supplementary Table 8. Spearman correlation coefficients for the EHRA score and its 
components with PACT- Q items (continued) 
EHRA Score Anxiety Chest pain Palpitations Dyspnoea Fatigue Dizziness 
 
 [D3] How did your experience with side effects such as minor bruises or bleeding (e.g., 
while shaving, cooking, after small cuts) compare to what you expected? 
-0.13079
<0.0001
-0.13910
<0.0001
-0.09285
<0.0001
-0.12041
<0.0001
0.11865 
<0.0001 
-0.12903
<0.0001
-0.07451
<0.0001
[D4] Regarding the follow-up of your disease and anticoagulant treatment, how satisfied  
are you with your level of independence? 
-0.15334
<0.0001
-0.15450
<0.0001
-0.13176
<0.0001
-0.14687
<0.0001
-0.12468
<0.0001
-0.13208
<0.0001
-0.08783
<0.0001
[D5] How satisfied are you with the methods (e.g., appointments with nurses, doctors, 
labs) used to ensure the follow-up of your disease and anticoagulant treatment? 
-0.08021
<0.0001
-0.11282
<0.0001
-0.12734
<0.0001
-0.14360
<0.0001
-0.07482
<0.0001
-0.07624
<0.0001
-0.07045
<0.0001
[D6] How satisfied are you with the form of your anticoagulant treatment (oral pill / 
injection)?      
-0.11068
<0.0001
-0.14048
<0.0001
-0.14555
<0.0001
-0.14001
<0.0001
-0.09524
<0.0001
-0.10708
<0.0001
-0.06141
<0.0001
[D7] Overall, how satisfied are you with your anticoagulant treatment? 
-0.11068
<0.0001
-0.15982
<0.0001
-0.12879
<0.0001
-0.15225
<0.0001
-0.11041
<0.0001
-0.11477
<0.0001
-0.05738
0.0001
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Supplementary Table 9. Unadjusted logistic regression analyses for EHRA score (Categories 3/4 
versus 1/2) and EHRA symptom dimensions separately in relation to interventions to restore sinus 
rhythm at one year 
Variable Odds ratio 
EHRA 3/4 
versus 1/2 
95%  
Confidence interval 
P Value P Value  
unadjusted logistic 
regression across 
all 4 categories 
Cardioversion, N=701 
Palpitations 1.75 1.46 2.10 <0.0001 <0.0001 
Fatigue 1.19 1.01 1.40 0.04 0.02 
Dizziness 1.17 0.92 1.47 0.20 0.08 
Dyspnea 1.07 0.90 1.27 0.45 0.74 
Chest pain 1.45 1.06 1.98 0.02 0.13 
Anxiety 0.91 0.74 1.12 0.36 0.24 
EHRA score 1.32 1.12 1.55 0.0008 0.009 
Catheter-based 
ablation, N=226 
Palpitations 2.76 2.09 3.65 <0.0001 <0.0001 
Fatigue 1.47 1.12 1.92 0.005 0.04 
Dizziness 1.08 0.72 1.61 0.73 0.68 
Dyspnea 0.90 0.67 1.21 0.48 0.41 
Chest pain 1.42 0.84 2.40 0.19 0.57 
Anxiety 1.30 0.94 1.80 0.11 0.46 
EHRA score 1.76 1.33 2.34 <0.0001 0.0003 
Sinus rhythm at one 
year, N=2022 
Palpitations 1.91 1.67 2.18 <0.0001 <0.0001 
Fatigue 0.84 0.75 0.94 0.003 0.002 
Dizziness 0.75 0.63 0.90 0.002 0.002 
Dyspnea 0.69 0.61 0.78 <0.0001 <0.0001 
Chest pain 1.22 0.96 1.55 0.11 0.06 
Anxiety 1.17 1.02 1.34 0.03 0.0009 
EHRA score 0.99 0.89 1.10 0.84 0.01 
Adequate heart rate 
control, N=2734 
Palpitations 0.81 0.70 0.95 0.01 0.01 
Fatigue 0.91 0.80 1.03 0.14 0.21 
Dizziness 0.99 0.81 1.20 0.90 0.28 
Dyspnea 0.93 0.81 1.06 0.28 0.70 
Chest pain 0.81 0.61 1.07 0.14 0.25 
Anxiety 0.97 0.83 1.14 0.72 0.10 
EHRA score 0.85 0.75 0.96 0.008 0.02 
Odds ratios are provided for EHRA score category 3/4 versus 1/2 in an unadjusted model. 
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Supplementary Table 10. Unadjusted logistic regression analyses for EHRA score (Categories 3/4 
versus 1/2) and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one 
year 
Variable Odds ratio 
EHRA 3/4 
versus 1/2 
95%  
Confidence interval 
P Value P Value 
unadjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 1.04 0.67 1.60 0.87 0.12 
Fatigue 1.35 0.95 1.91 0.09 0.40 
Dizziness 1.52 0.97 2.40 0.07 0.0002 
Dyspnea 1.51 1.07 2.14 0.02 0.08 
Chest pain 2.13 1.21 3.75 0.009 <0.0001 
Anxiety 0.73 0.45 1.19 0.21 0.09 
EHRA score 1.39 0.98 1.97 0.07 0.06 
Coronary events, 
N=140 
Palpitations 0.81 0.51 1.29 0.38 0.52 
Fatigue 1.33 0.94 1.87 0.11 0.32 
Dizziness 1.24 0.77 2.00 0.38 0.51 
Dyspnea 1.68 1.19 2.36 0.0029 <0.0001 
Chest pain 3.15 1.94 5.13 <0.0001 <0.0001 
Anxiety 1.19 0.79 1.80 0.42 0.72 
EHRA score 1.65 1.16 2.35 0.005 0.009 
Heart failure, N=155 
Palpitations 1.11 0.74 1.66 0.61 0.68 
Fatigue 1.96 1.42 2.71 <0.0001 0.0002 
Dizziness 1.53 0.97 2.41 0.07 0.08 
Dyspnea 2.53 1.82 3.51 <0.0001 <0.0001 
Chest pain 1.10 0.51 2.39 0.81 0.40 
Anxiety 1.73 1.20 2.50 0.004 0.02 
EHRA score 1.72 1.24 2.39 0.001 0.001 
Major bleeding, N=168 
Palpitations 0.80 0.52 1.22 0.30 0.63 
Fatigue 1.42 1.04 1.95 0.03 0.05 
Dizziness 1.18 0.75 1.85 0.47 0.73 
Dyspnea 1.20 0.87 1.66 0.26 0.09 
Chest pain 1.03 0.52 2.03 0.94 0.67 
Anxiety 1.24 0.85 1.81 0.26 0.33 
EHRA score 1.26 0.92 1.72 0.15 0.11 
Odds ratios are provided for EHRA score category 3/4 versus 1/2 in an unadjusted model. Coronary 
events comprised acute coronary syndrome and coronary revascularization. The model for incident heart 
failure does not include adjustment for heart failure. 
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Supplementary Table 11. Multivariable-adjusted logistic regression analyses for EHRA score (category 
2 versus 1) and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one 
year 
Variable Odds ratio 
EHRA 2 
versus 1 
95%  
Confidence interval 
P Value P Value  
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 1.41 0.93 2.12 0.11 0.29 
Fatigue 0.89 0.55 1.44 0.63 0.92 
Dizziness 1.77 1.19 2.62 0.005 0.002 
Dyspnea 0.85 0.53 1.37 0.51 0.59 
Chest pain 1.94 1.32 2.84 0.0008 0.002 
Anxiety 1.29 0.88 1.91 0.20 0.08 
EHRA score 0.43 0.23 0.81 0.009 0.05 
Coronary events, 
N=140 
Palpitations 1.43 0.96 2.14 0.08 0.21 
Fatigue 0.81 0.51 1.30 0.38 0.73 
Dizziness 1.22 0.82 1.80 0.32 0.72 
Dyspnea 1.10 0.68 1.78 0.69 0.02 
Chest pain 1.51 1.01 2.24 0.04 <0.0001 
Anxiety 1.14 0.76 1.72 0.53 0.33 
EHRA score 0.84 0.40 1.77 0.64 0.12 
Heart failure, N=155 
Palpitations 1.06 0.72 1.55 0.77 0.42 
Fatigue 0.70 0.45 1.10 0.12 0.0006 
Dizziness 1.28 0.88 1.86 0.20 0.19 
Dyspnea 1.26 0.81 1.95 0.30 <0.0001 
Chest pain 1.10 0.73 1.65 0.65 0.42 
Anxiety 1.02 0.68 1.53 0.94 0.032 
EHRA score 0.54 0.30 0.99 0.05 0.005 
Major bleeding, N=168 
Palpitations 1.04 0.72 1.49 0.85 0.78 
Fatigue 1.42 0.88 2.29 0.15 0.28 
Dizziness 1.13 0.78 1.62 0.53 0.90 
Dyspnea 1.10 0.72 1.68 0.66 0.61 
Chest pain 1.14 0.78 1.66 0.50 0.74 
Anxiety 1.08 0.74 1.59 0.69 0.46 
EHRA score 1.49 0.70 3.18 0.30 0.60 
Odds ratios are provided for EHRA score category 2 versus 1 in a multivariable-adjusted model. Covariates 
are age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, 
heart failure, history of myocardial infarction. Coronary events comprised acute coronary syndrome and 
coronary revascularization. The model for incident heart failure does not include adjustment for heart 
failure.  
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Supplementary Table 12. Multivariable-adjusted logistic regression analyses for EHRA score (category 3 
versus 1) and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one year 
Variable Odds ratio 
EHRA 3 
versus 1 
95%  
Confidence interval 
P Value P Value  
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 1.29 0.73 2.29 0.38 0.29 
Fatigue 1.01 0.60 1.69 0.97 0.92 
Dizziness 1.28 0.68 2.41 0.45 0.002 
Dyspnea 1.06 0.64 1.77 0.81 0.59 
Chest pain 2.37 1.24 4.55 0.01 0.002 
Anxiety 0.61 0.32 1.17 0.14 0.08 
EHRA score 0.58 0.31 1.07 0.08 0.05 
Coronary events, 
N=140 
Palpitations 1.02 0.54 1.93 0.95 0.21 
Fatigue 0.91 0.55 1.51 0.71 0.73 
Dizziness 1.30 0.73 2.32 0.37 0.72 
Dyspnea 1.01 0.57 1.78 0.97 0.02 
Chest pain 1.93 0.96 3.88 0.06 <0.0001 
Anxiety 1.35 0.78 2.34 0.28 0.33 
EHRA score 1.10 0.52 2.32 0.80 0.12 
Heart failure, N=155 
Palpitations 0.95 0.53 1.71 0.88 0.42 
Fatigue 1.29 0.81 2.06 0.28 0.0006 
Dizziness 1.52 0.85 2.72 0.15 0.19 
Dyspnea 2.69 1.70 4.26 <0.0001 <0.0001 
Chest pain 0.92 0.33 2.55 0.87 0.42 
Anxiety 1.54 0.94 2.52 0.09 0.03 
EHRA score 0.92 0.51 1.65 0.77 0.005 
Major bleeding, N=168 
Palpitations 0.78 0.43 1.41 0.41 0.78 
Fatigue 1.54 0.92 2.57 0.10 0.28 
Dizziness 1.11 0.64 1.95 0.71 0.90 
Dyspnea 0.85 0.50 1.43 0.53 0.61 
Chest pain 0.80 0.32 2.00 0.63 0.74 
Anxiety 1.43 0.88 2.3 0.15 0.46 
EHRA score 1.40 0.65 3.01 0.39 0.60 
Odds ratios are provided for EHRA score category 3 versus 1 in a multivariable-adjusted model. Covariates 
are age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, 
heart failure, history of myocardial infarction. Coronary events comprised acute coronary syndrome and 
coronary revascularization. The model for incident heart failure does not include adjustment for heart 
failure. 
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Supplementary Table 13. Multivariable-adjusted logistic regression analyses for EHRA score (category 
4 versus 1) and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one 
year 
Variable Odds ratio 
EHRA 4 versus 
1 
95%  
Confidence interval 
P Value P Value  
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 0.77 0.29 2.01 0.59 0.29 
Fatigue 0.89 0.47 1.67 0.71 0.92 
Dizziness 3.42 1.62 7.20 0.001 0.002 
Dyspnoea 0.73 0.38 1.40 0.35 0.59 
Chest pain 1.18 0.16 8.87 0.87 0.002 
Anxiety 0.65 0.25 1.66 0.37 0.08 
EHRA score 0.46 0.24 0.89 0.02 0.05 
Coronary events, 
N=140 
Palpitations 1.75 0.79 3.86 0.17 0.21 
Fatigue 1.08 0.60 1.94 0.80 0.73 
Dizziness 1.12 0.39 3.17 0.84 0.72 
Dyspnoea 2.09 1.19 3.66 0.01 0.02 
Chest pain 8.46 3.48 20.56 <0.0001 <0.0001 
Anxiety 1.85 0.91 3.75 0.09 0.33 
EHRA score 1.50 0.70 3.20 0.29 0.12 
Heart failure, 
N=155 
Palpitations 1.71 0.88 3.32 0.11 0.42 
Fatigue 2.10 1.22 3.63 0.008 0.0006 
Dizziness 1.98 0.88 4.47 0.10 0.19 
Dyspnoea 2.50 1.34 4.67 0.004 <0.0001 
Chest pain 2.76 0.81 9.42 0.10 0.42 
Anxiety 2.24 1.21 4.16 0.01 0.032 
EHRA score 1.25 0.67 2.32 0.49 0.005 
Major bleeding, N=168 
Palpitations 1.24 0.58 2.66 0.59 0.78 
Fatigue 1.77 0.98 3.20 0.06 0.28 
Dizziness 1.22 0.48 3.10 0.67 0.90 
Dyspnoea 1.23 0.70 2.16 0.48 0.61 
Chest pain 1.78 0.42 7.56 0.44 0.74 
Anxiety 0.83 0.35 1.95 0.66 0.46 
EHRA score 1.74 0.79 3.83 0.17 0.60 
Odds ratios are provided for EHRA score category 4 versus 1 in a multivariable-adjusted model. Covariates 
are age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, 
heart failure, history of myocardial infarction. Coronary events comprised acute coronary syndrome and 
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coronary revascularization. The model for incident heart failure does not include adjustment for heart 
failure. 
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Supplementary Table 14. Unadjusted logistic regression analyses for EHRA score (category 2 versus 1) 
and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one year 
Variable Odds ratio 
EHRA 2 
versus 1 
95% 
Confidence interval 
P Value P Value  
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 1.54 1.04 2.29 0.03 0.12 
Fatigue 1.01 0.65 1.59 0.96 0.40 
Dizziness 1.94 1.34 2.82 0.0005 0.0002 
Dyspnoea 1.00 0.64 1.54 0.99 0.08 
Chest pain 2.19 1.52 3.16 <0.0001 <0.0001 
Anxiety 1.50 1.04 2.17 0.03 0.09 
EHRA score 0.52 0.28 0.95 0.03 0.06 
Coronary events, 
N=140 
Palpitations 1.20 0.83 1.73 0.35 0.52 
Fatigue 0.92 0.60 1.43 0.72 0.32 
Dizziness 1.26 0.87 1.82 0.22 0.51 
Dyspnoea 1.32 0.85 2.06 0.22 <0.0001 
Chest pain 2.03 1.41 2.94 0.0002 <0.0001 
Anxiety 1.48 0.76 2.91 0.73 0.72 
EHRA score 0.92 0.44 1.92 0.83 0.009 
Heart failure, N=155 
Palpitations 0.98 0.69 1.41 0.92 0.68 
Fatigue 0.78 0.51 1.19 0.25 0.0002 
Dizziness 1.30 0.91 1.86 0.15 0.08 
Dyspnoea 1.37 0.90 2.07 0.14 <0.0001 
Chest pain 1.13 0.77 1.66 0.54 0.40 
Anxiety 1.05 0.72 1.55 0.79 0.02 
EHRA score 0.57 0.32 1.01 0.05 0.001 
Major bleeding, N=168 
Palpitations 0.92 0.66 1.29 0.64 0.63 
Fatigue 1.44 0.94 2.22 0.10 0.05 
Dizziness 1.14 0.81 1.60 0.45 0.73 
Dyspnoea 1.23 0.84 1.81 0.28 0.09 
Chest pain 1.22 0.86 1.73 0.26 0.67 
Anxiety 1.12 0.79 1.60 0.51 0.33 
EHRA score   1.62 0.77 3.40 0.21 0.11 
Odds ratios are provided for EHRA score category 2 versus 1 in an unadjusted model. Coronary events 
comprised acute coronary syndrome and coronary revascularization. The model for incident heart failure 
does not include adjustment for heart failure. 
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Supplementary Table 15. Unadjusted logistic regression analyses for EHRA score (category 3 versus 1) 
and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one year 
Variable Odds ratio 
EHRA 3 
versus 1 
95%  
Confidence interval 
P Value P Value  
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
Thromboembolic events, 
N=136 
Palpitations 1.51 0.89 2.58 0.13 0.12 
Fatigue 1.39 0.86 2.23 0.18 0.40 
Dizziness 1.59 0.88 2.88 0.13 0.0002 
Dyspnoea 1.67 1.06 2.62 0.0258 0.08 
Chest pain 3.08 1.68 5.64 0.0003 <0.0001 
Anxiety 0.84 0.46 1.53 0.56 0.09 
EHRA score 0.88 0.49 1.57 0.65 0.06 
Coronary events, 
N=140 
Palpitations 0.80 0.44 1.45 0.46 0.52 
Fatigue 1.16 0.73 1.87 0.53 0.32 
Dizziness 1.40 0.81 2.43 0.23 0.51 
Dyspnoea 1.28 0.76 2.16 0.35 <0.0001 
Chest pain 3.04 1.66 5.56 0.0003 <0.0001 
Anxiety 1.12 0.67 1.87 0.68 0.72 
EHRA score 1.31 0.64 2.68 0.47 0.009 
Heart failure, N=155 
Palpitations 0.96 0.57 1.62 0.87 0.68 
Fatigue 1.52 0.99 2.35 0.06 0.0002 
Dizziness 1.46 0.83 2.56 0.19 0.08 
Dyspnoea 2.97 1.93 4.57 <0.0001 <0.0001 
Chest pain 0.80 0.29 2.19 0.66 0.40 
Anxiety 1.60 1.01 2.53 0.05 0.02 
EHRA score 0.96 0.55 1.69 0.90 0.001 
Major bleeding, N=168 
Palpitations 0.70 0.41 1.19 0.19 0.63 
Fatigue 1.71 1.07 2.71 0.02 0.05 
Dizziness 1.18 0.70 2.00 0.54 0.73 
Dyspnoea 1.09 0.68 1.72 0.73 0.09 
Chest pain 1.00 0.46 2.17 0.99 0.67 
Anxiety 1.47 0.95 2.28 0.08 0.33 
EHRA score 1.66 0.79 3.52 0.18 0.11 
Odds ratios are provided for EHRA score category 3 versus 1 in an unadjusted model. Coronary events 
comprised acute coronary syndrome and coronary revascularization. The model for incident heart failure 
does not include adjustment for heart failure. 
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Supplementary Table 16. Unadjusted logistic regression analyses for EHRA score (category 4 versus 1) 
and EHRA symptom dimensions separately in relation to cardiovascular outcomes at one year 
Variable Odds ratio 
EHRA 4 
versus 1 
95% 
Confidence interval 
P Value P Value 
adjusted logistic 
regression across 
all 4 categories 
Stroke/TIA/arterial  
thromboembolic events, 
N=136 
Palpitations 0.90 0.35 2.29 0.82 0.12 
Fatigue 1.30 0.72 2.36 0.39 0.40 
Dizziness 3.65 1.77 7.54 0.0004 0.0002 
Dyspnoea 1.23 0.68 2.21 0.49 0.08 
Chest pain 1.20 0.16 8.83 0.86 <0.0001 
Anxiety 0.97 0.42 2.26 0.94 0.09 
EHRA score 0.77 0.41 1.45 0.42 0.06 
Coronary events, 
N=140 
Palpitations 1.16 0.54 2.46 0.71 0.52 
Fatigue 1.48 0.85 2.56 0.16 0.32 
Dizziness 1.21 0.44 3.35 0.72 0.51 
Dyspnoea 3.17 1.96 5.15 <0.0001 <0.0001 
Chest pain 9.42 4.11 21.59 <0.0001 <0.0001 
Anxiety 1.48 0.76 2.91 0.25 0.72 
EHRA score 1.92 0.93 3.95 0.08 0.009 
Heart failure, N=155 
Palpitations 1.44 0.76 2.72 0.26 0.68 
Fatigue 2.17 1.31 3.61 0.003 0.0002 
Dizziness 2.36 1.11 5.01 0.03 0.08 
Dyspnoea 2.89 1.66 5.04 0.0002 <0.0001 
Chest pain 2.59 0.78 8.59 0.12 0.40 
Anxiety 2.17 1.20 3.91 0.01 0.03 
EHRA score 1.36 0.77 2.42 0.29 0.001 
Major bleeding, N=168 
Palpitations 0.94 0.46 1.90 0.86 0.63 
Fatigue 2.00 1.17 3.42 0.01 0.05 
Dizziness 1.45 0.63 3.37 0.38 0.73 
Dyspnoea 1.82 1.13 2.93 0.01 0.09 
Chest pain 1.52 0.37 6.32 0.57 0.67 
Anxiety 0.88 0.40 1.92 0.74 0.33 
EHRA score 2.26 1.06 4.82 0.04 0.11 
Odds ratios are provided for EHRA score category 4 versus 1 in an unadjusted model. Coronary events 
comprised acute coronary syndrome and coronary revascularization. The model for incident heart failure 
does not include adjustment for heart failure 
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